Signal from the log
Pathos AI
237 M$ · Series D and later · United States · Biotech
Pathos AI, à New York, se sert de sa plateforme d'IA, Foundry, pour repérer et acquérir des médicaments en développement, puis les mener elle même en essais : quatre candidats sont en clinique, surtout en cancérologie. La levée est menée par Bristol Myers Squibb, avec une valorisation d'environ 3 Md$ après la levée.
Verified
Announced on , logged by the watch of 23 October 2026.
- Operation
- Funding round
- Announced amount
- 237 M$
- Stage
- Series D and later
- Country
- United States
- Sector
- Biotech
What the log says
Editorial note, in French
Communiqué ouvert, montant relu et fonds nommés.
The investors
Led by Bristol Myers Squibb
Provenance
Logged on 23 October 2026
Description Written in French during the watch run. Written during the watch run, after reading the issuer's press release or the source article.
Verification Amounts and fund names were double checked against the issuer's press release or an official filing.
What this status means
Verified The press release was opened: amount double checked, funds named. The article remains to be written.
The rule A signal is never removed from the log. A round set aside stays readable with its reason, because a collection you cannot reread is a collection you cannot correct.